Altuviiio Update

Altuviiio (efanesoctocog alfa) continues to impress in difficult-to-treat patients. A French real-world study reported that once-weekly Altuviiio reduced treated bleeds by about 89% and joint bleeds by about 85% in hemophilia A patients whose previous prophylaxis wasn’t adequately controlling their bleeding. 

Source: LA Kelley Communications, Inc., Communique, August 2026